Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

pan-KRAS inhibitor

DRUG CLASS:

pan-KRAS inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	trametinib + BI 1701963 Sensitive: D – Preclinical trametinib + BI 1701963 Sensitive : D	trametinib + BI 1701963 Sensitive: D – Preclinical trametinib + BI 1701963 Sensitive : D
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	YL-17231 Sensitive: D – Preclinical YL-17231 Sensitive : D	YL-17231 Sensitive: D – Preclinical YL-17231 Sensitive : D
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	BI-2493 Sensitive: D – Preclinical BI-2493 Sensitive : D	BI-2493 Sensitive: D – Preclinical BI-2493 Sensitive : D
KRAS G12D	Solid Tumor	KRAS G12D	Solid Tumor	BI-2493 Sensitive: D – Preclinical BI-2493 Sensitive : D	BI-2493 Sensitive: D – Preclinical BI-2493 Sensitive : D
KRAS A146V	Solid Tumor	KRAS A146V	Solid Tumor	BI-2493 Sensitive: D – Preclinical BI-2493 Sensitive : D	BI-2493 Sensitive: D – Preclinical BI-2493 Sensitive : D
KRAS G12V	Solid Tumor	KRAS G12V	Solid Tumor	BI-2493 Sensitive: D – Preclinical BI-2493 Sensitive : D	BI-2493 Sensitive: D – Preclinical BI-2493 Sensitive : D